RARyo Akiyama

Ryo Akiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryo Akiyama has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Bioresorbable magnesium flow diverter promotes early aneurysm occlusion in rabbits

    by So Matsukawa, Akira Ishii, Ryo Akiyama, Natsuhi Sasaki, Hidehisa Nishi, Hideo Chihara, Tomoko Hayashi, Yoshihito Kawamura, Shinichi Yagi, Shin-Ichi Inoue, et al.

    Background: Bioresorbable flow diverters (BRFDs) may overcome the limitations of permanent flow diverters (FDs). We developed a long period stacking ordered-type magnesium (Mg) alloy with superior strength, processability, and corrosion resistance using rapidly solidified powder metallurgy. Thin Mg wires were coated with poly L-lactic acid (PLLA) by electrospinning to extend bioresorption, and braided into 48 wire Mg-BRFDs. Methods: We compared mechanical properties, angiographic outcomes, and biological responses of Mg-BRFDs with cobalt–chromium/platinum–tungsten FDs (CoCr-FDs) in a rabbit elastase induced aneurysm model and abdominal aorta. Assessments included angiography, optical coherence tomography, scanning electron microscopy, and histopathology at 0.5, 1, and 3 months. Results: Mg-BRFDs had a mean strut diameter of 56 µm (including a 10 µm PLLA coating), porosity of 53.9%, and pore density of 23 pores/mm². Complete occlusion rates in CoCr-FDs were 20% (1/5), 0% (0/7), and 57% (4/7) at 0.5, 1, and 3 months, respectively; corresponding rates with Mg-BRFDs were 50% (3/6), 75% (6/8), and 100% (8/8). Among cases with incomplete occlusion, neointimal coverage rate of the aneurysm neck was significantly greater with Mg-BRFDs (median 70.2% vs 26.1%, P=0.006). No occlusion of side branches covered by FDs occurred in either group. Neointimal ionized calcium binding adapter molecule 1 (Iba-1) positive cell counts were higher with Mg-BRFDs but declined over time (P=0.0003). Conclusions: Mg-BRFDs promoted early neointimal formation during bioresorption, leading to faster and more complete aneurysm occlusion than CoCr-FDs. These findings demonstrate the feasibility of Mg-BRFDs as a promising next generation therapeutic strategy.


  • Open Access

    A Case of Successful Stent Retriever Angioplasty Using the Tigertriever for Acute M1 Segment Occlusion of the Middle Cerebral Artery due to Atherosclerotic Disease

    by Ryo Akiyama, Sou Sawamura, Daisuke Yamada, Kohei Tsujino, Hidetoshi Matsukawa, Fuminori Shimizu, Yoshinori Akiyama, Takashi Yoshida, Nobuyuki Sakai

    Objective: The optimal treatment strategy for acute ischemic stroke due to intracranial atherosclerotic disease (ICAD-AIS) has not been established. The Tigertriever (Rapid Medical, Yokneam, Israel) is a unique stent retriever (SR) that allows manual adjustment of radial expansion force, a feature that may be advantageous for the treatment of ICAD-AIS. We report a case of ICAD-AIS successfully treated with SR angioplasty using the Tigertriever.Case Presentation: A 71-year-old man developed sudden-onset left hemiplegia and was transported to our hospital 38 min after symptom onset. The National Institutes of Health Stroke Scale score was 13. MRA demonstrated occlusion of the right M1 segment of the middle cerebral artery (MCA), and diffusion-weighted imaging (DWI) showed faint hyperintensity in the posterior corona radiata. DSA revealed occlusion of the distal right M1 segment with good leptomeningeal collateral flow to the MCA territory. Given the patient’s multiple atherosclerotic risk factors, the occlusion was clinically suspected to be associated with ICAD. After administration of aspirin (200 mg) and prasugrel (20 mg), SR angioplasty was performed using a Tigertriever 17. Postprocedural DSA demonstrated residual stenosis of approximately 50%; however, no recoil or re-occlusion was observed. The puncture-to-recanalization time was 23 min. Postprocedural DWI showed only a small hyperintense lesion in the right putamen, with no evidence of re-occlusion. The patient was discharged home on day 11 with a modified Rankin Scale (mRS) of 0. The post-procedure antiplatelet regimen was aspirin (100 mg) plus prasugrel (3.75 mg) for 1 month, followed by aspirin (100 mg) plus cilostazol (200 mg) until 6 months, and aspirin (100 mg) alone thereafter. During the 9-month follow-up, the mRS remained 0 without re-occlusion of the stenotic lesion.Conclusion: The Tigertriever may enable effective angioplasty for intracranial atherosclerotic stenotic lesions by allowing controlled adjustment of radial expansion force. This device may represent a promising therapeutic option for the treatment of ICAD-AIS.


  • Open Access

    Early Clinical Experience with Carotid Artery Stenting for Internal Carotid Artery Stenosis Using the Protcas GW Protection System

    by Ryo Akiyama, Sou Sawamura, Daisuke Yamada, Kohei Tsujino, Hidetoshi Matsukawa, Fuminori Shimizu, Yoshinori Akiyama, Takashi Yoshida, Nobuyuki Sakai

    Objective: Carotid artery stenting (CAS) using a distal balloon protection device (DBPD), which had been widely used in Japan, became difficult to perform after the discontinuation of the PercuSurge GuardWire (Medtronic, Minneapolis, MN, USA) in April 2021. The Protcas GW protection device (SB-KAWASUMI LABORATORIES, Kanagawa, Japan) was subsequently developed as a new DBPD; however, its clinical use has not yet been reported. In this study, we describe our initial clinical experience with the Protcas GW and evaluate its efficacy and safety in real-world practice.Methods: We retrospectively analyzed consecutive patients who underwent CAS using the Protcas GW between April 15, 2025 and August 31, 2025 at a single center in Japan. Patient demographics, characteristics of the stenotic lesions, and procedural details were collected. Clinical outcomes included technical success, device-related adverse events, and the composite of any stroke, myocardial infarction, or death during the periprocedural period.Results: A total of 10 patients were included. The median age was 76 years (interquartile range [IQR], 75–84), and the cohort consisted of 9 men and 1 woman. Eight patients had symptomatic stenosis. The median North American Symptomatic Carotid Endarterectomy Trial (NASCET) stenosis severity was 56.5% (IQR, 52.3–65.3), and unstable plaque was identified in 5 cases. The median plaque length was 18.5 mm (IQR, 15–23.8 mm). CAS using the Protcas GW was successful in all cases. One case required device replacement due to inadequate distal balloon inflation; no other device-related adverse events were observed. No periprocedural events occurred in the composite outcome of any stroke, myocardial infarction, or death. Asymptomatic diffusion-weighted imaging-positive lesions were detected in 3 cases on postoperative MRI, with lesion counts of 1, 1, and 2, respectively.Conclusion: In this initial clinical experience, CAS performed using the Protcas GW device was completed successfully without major device-related adverse events, indicating that the procedure can be performed safely.

  • Open Access

    Pipeline shield reduces diffusion-weighted imaging-detected ischemia after intracranial aneurysm treatment compared with pipeline flex: a propensity score-matched retrospective cohort study

    by Ryo Akiyama, Akira Ishii, Hideo Chihara, Chiaki Sakai, Takayuki Kikuchi, Masakazu Okawa, Taichi Ikedo, Shigeki Takada, So Matsukawa, Yoshiki Arakawa

    Background The Pipeline Flex embolization device with Shield technology (PED Shield, Medtronic, Irvine, CA, USA) is a flow diverter designed to reduce thrombogenicity through phosphorylcholine surface modification. Although in vitro and in vivo studies have demonstrated the thrombogenicity reducing effects of this technology, its effectiveness in real-world clinical practice remains unclear. This study aims to compare the number of post-procedure diffusion-weighted imaging (DWI)-positive lesions between PED Flex(Medtronic, Irvine, CA, USA) and PED Shield to assess the impact of surface modification. Methods This retrospective cohort study included patients with unruptured intracranial aneurysms treated with PED Flex or PED Shield between April 2016 and March 2024 at a single institution. Propensity score matching was performed to control for confounders, and the number of post-procedure DWI-positive lesions was evaluated as the primary outcome. Results In total, 148 procedures (132 patients, 138 aneurysms) were included, with 68 (46%) treated with PED Flex and 80 (54%) with PED Shield. Propensity score matching resulted in 47 matched pairs. After matching, the median number of post-procedure DWI-positive lesions was nine (interquartile range (IQR): 3–17) in the PED Flex group and three (IQR: 1–6) in the PED Shield group, with a significantly lower number in the PED Shield group (regression coefficient β = −10.70 [95% confidence interval (CI): −16.23 to −5.16), PConclusion After adjusting for confounders, the PED Shield group had significantly fewer post-procedure DWI-positive lesions than the PED Flex group, suggesting that phosphorylcholine surface modification technology may reduce thrombogenicity in real-world clinical practice.


  • Open Access

    Magnesium-based bioresorbable flow diverter for intracranial aneurysms: a pilot study of biocompatibility and bioresorption in a rabbit vascular model

    by Ryo Akiyama, Akira Ishii, Natsuhi Sasaki, So Matsukawa, Shinichi Yagi, Hideo Chihara, Hidehisa Nishi, Kiyotaka Iwasaki, Shinichi Sakurai, Yoshihito Kawamura, et al.

    Background: Bioresorbable flow diverters (BRFDs) have the potential to solve several problems associated with conventional permanent flow diverters. We have constructed bare and poly-L-lactic acid (PLLA)-coated magnesium BRFDs (MgBRFDs) using a high-strength corrosion-resistant magnesium alloy. This study aimed to compare bioresorption and biocompatibility between the two types in a rabbit vascular model to determine which is more clinically feasible in humans. Methods: Bare and PLLA-coated MgBRFDs were fabricated by braiding 48 thin magnesium alloy wires. Mechanical testing was conducted. Bare (n=13) and PLLA-coated (n=13) MgBRFDs were implanted into rabbit aortas and harvested 14, 30, and 90 days after implantation. The physical structure of the resolution process was examined using optical coherence tomography (OCT), micro-computed tomography, and scanning electron microscopy (SEM). The biological response of the vascular tissue was examined using SEM and histopathological analysis. Results: The porosity and pore density of the bare MgBRFD were 64% and 16 pores/mm 2 , respectively; corresponding values for the PLLA-coated MgBRFD were 63% and 12 pores/mm 2 , respectively. The OCT attenuation score was significantly higher for the PLLA-coated MgBRFD at all time points (14 days, P=0.01; 30 days, P=0.02; 90 days, P=0.004). OCT, micro-computed tomography, and SEM demonstrated better stent structure preservation with the PLLA-coated MgBRFD. Neointimal thickness did not significantly change over time in either type of MgBRFD (bare, P=0.93; PLLA-coated, P=0.34); however, the number of inflammatory and proliferative cells peaked at 14 days and then decreased. Conclusions: Both bare and PLLA-coated MgBRFDs had excellent biocompatibility. The PLLA-coated MgBRFD has greater clinical feasibility because of its delayed bioresorption.


  • Bioresorbable Poly (L-Lactic Acid) Flow Diverter Versus Cobalt-Chromium Flow Diverter: In Vitro and In Vivo Analysis

    by Natsuhi Sasaki, Akira Ishii, Shinichi Yagi, Hidehisa Nishi, Ryo Akiyama, Masakazu Okawa, Yu Abekura, Hirofumi Tsuji, Shinichi Sakurai, Susumu Miyamoto

    Background: Permanent metallic flow diverter (FD) implantation for treatment of intracranial aneurysms requires antiplatelet therapy for an unclear duration and restricts postprocedural endovascular access. Bioresorbable FDs are being developed as a solution to these issues, but the biological reactions and phenomena induced by bioresorbable FDs have not been compared with those of metallic FDs. Methods: We have developed a bioresorbable poly (L-lactic acid) FD (PLLA-FD) and compared it with an FD composed of cobalt-chromium and platinum-tungsten (CoCr-FD). FD mechanical performance and in vitro degradation of the PLLA-FD were evaluated. For in vivo testing in a rabbit aneurysm model, FDs were implanted at the aneurysm site and the abdominal aorta in the PLLA-FD group (n=21) and CoCr-FD group (n=15). Aneurysm occlusion rate, branch patency, and thrombus formation within the FD were evaluated at 3, 6, and 12 months. Local inflammation and neointima structure were also evaluated. Results: Mean strut, porosity, and pore density for the PLLA-FD were 41.7 μm, 60%, and 20 pores per mm 2 , respectively. The proportion of aneurysms exhibiting a neck remnant or complete occlusion did not significantly differ between the groups; however, the complete occlusion rate was significantly higher in the PLLA-FD group (48% versus 13%; P =0.0399). Branch occlusion and thrombus formation within the FD were not observed in either group. In the PLLA-FD group, CD68 immunoreactivity was significantly higher, but neointimal thickness decreased over time and did not significantly differ from that of the CoCr-FD at 12 months. Collagen fibers significantly predominated over elastic fibers in the neointima in the PLLA-FD group. The opposite was observed in the CoCr-FD group. Conclusions: The PLLA-FD was as effective as the CoCr-FD in this study and is feasible for aneurysm treatment. No morphological or pathological problems were observed with PLLA-FD over a 1-year period.


  • Open Access

    Onset-to-treatment time and aneurysmal regression predict improvement of cranial neuropathy after flow diversion treatment in patients with symptomatic internal carotid artery aneurysms

    by Ryo Akiyama, Akira Ishii, Takayuki Kikuchi, Masakazu Okawa, Yukihiro Yamao, Yu Abekura, Isao Ono, Natsuhi Sasaki, Hirofumi Tsuji, Hirotoshi Imamura, et al.

    Background Although flow diversion plays a pivotal role in treating internal carotid artery aneurysms presenting with cranial neuropathy, predictors of symptom improvement have not been established. Objective To investigate improvement of symptoms after flow diversion treatment in patients with internal carotid artery aneurysms causing cranial neuropathy, with sufficient follow-up period. Additionally, to examine factors associated with improvement of symptoms. Methods This retrospective multicenter study examined patients with unruptured internal carotid artery aneurysms presenting with cranial neuropathy who were treated using flow diversion and followed up for at least 12 months. Study outcomes were transient worsening of symptoms and symptom status 12 months after treatment. Patient and aneurysm characteristics were statistically analyzed. Results Seventy-seven patients were included. Data needed for outcome analysis were available for 66 patients. At the 1-, 3-, 6-, 12-month, and last follow-ups, the proportion of patients with resolved or improved symptoms was 26% (20/77), 51% (39/77), 74% (57/77), 83% (64/77), and 79%(62/77), respectively. Symptom onset-to-treatment time Conclusions The rate of cranial neuropathy symptom improvement after flow diversion increased over the first 12 months after treatment, but not thereafter. Treatment within 6 months of symptom onset and aneurysmal regression were predictors of symptom improvement.


  • Open Access

    A Case of Thoracic Arachnoid Cyst with Thoracic Disc Herniation Presenting as Angina-like Pain

    by Nobuhiro Sasaki, Atsuhiko Toyoshima, Kiminori Sakurai, Ryota Motoie, Ryo Akiyama, Ken Ryu, Miyuki Fukuda, Shigeo Ueda, Hiroaki Manabe, Minoru Houshimaru

  • Predictors of Cerebral Aneurysm Rupture after Coil Embolization: Single-Center Experience with Recanalized Aneurysms

    by Y. Funakoshi, H. Imamura, S. Tani, H. Adachi, R. Fukumitsu, T. Sunohara, Y. Omura, Y. Matsui, N. Sasaki, T. Fukuda, et al.

    BACKGROUND AND PURPOSE: Recanalization after coil embolization is widely studied. However, there are limited data on how recanalized aneurysms rupture. Herein, we describe our experience with the rupture of recanalized aneurysms and discuss the type of recanalized aneurysms at greatest rupture risk. MATERIALS AND METHODS: A total of 426 unruptured aneurysms and 169 ruptured aneurysms underwent coil embolization in our institution between January 2009 and December 2017. Recanalization occurred in 38 (8.9%) of 426 unruptured aneurysms (unruptured group) and 37 (21.9%) of 169 ruptured aneurysms (ruptured group). The Modified Raymond-Roy classification on DSA was used to categorize the recanalization type. Follow-up DSA was scheduled until 6 months after treatment, and follow-up MRA was scheduled yearly. If recanalization was suspected on MRA, DSA was performed. RESULTS: In the unruptured group, the median follow-up term was 74.0 months. Retreatment for recanalization was performed in 18 aneurysms. Four of 20 untreated recanalized aneurysms (0.94% of total coiled aneurysms) ruptured. In untreated recanalized aneurysms, class IIIb aneurysms ruptured significantly more frequently than class II and IIIa (P = .025). In the ruptured group, the median follow-up term was 28.0 months. Retreatment for recanalization was performed in 16 aneurysms. Four of 21 untreated recanalized aneurysms (2.37% of total coiled aneurysms) ruptured. Class IIIb aneurysms ruptured significantly more frequently than class II and IIIa (P = .02). CONCLUSIONS: The types of recanalization after coil embolization may be predictors of rupture. Coiled aneurysms with class IIIb recanalization should undergo early retreatment because of an increased rupture risk.


  • Effect of Direct Neurologic Evaluation on Outcomes During Treatment of Unruptured Intracranial Aneurysms Under Local Anesthesia

    by Shuhei Kawabata, Hirotoshi Imamura, Shoichi Tani, Hidemitsu Adachi, So Tokunaga, Takayuki Funatsu, Keita Suzuki, Hiromasa Adachi, Natsuhi Sasaki, Yuichi Matsui, et al.